Incidence and Determinants of Nodule formation in continuous subcutaneous Foslevodopa/Foscarbidopa Infusion therapy.
Objective: This study aims to evaluate the incidence of subcutaneous (SC) nodules in Parkinson’s patients treated with continuous 24-hour SC infusion of foslevodopa/foscarbidopa (LDp/CDp) and…Intravenous L-dopa Administration in PD and DLB Patients with Oral Intake Difficulties: Current Status and Challenges
Objective: Investigation of efficacy and challenges of intravenous L-dopa therapy as an alternative treatment for PD patients and those with DLB who experience difficulty with…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Pharmacokinetic Analysis of Subcutaneous Levodopa/Carbidopa Delivery With ND0612
Objective: To (i) use a population pharmacokinetic (PK) model to compare predicted levodopa PK parameters when levodopa is delivered as investigational ND0612, as oral immediate-release…A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations
Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…Utilizing the Levodopa Challenge Test to Clarify Clinical Complaints Following Levodopa Administration: A Case Series
Objective: To characterize subjective clinical complaints reported by patients with Parkinson's Disease (PD) following levodopa administration and evaluate the utility of the levodopa challenge test…Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose
Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…The efficacy and safety of continuous subcutaneous infusion therapy with foslevodopa/foscarbidopa
Objective: To clarify the actual status of CSCI therapy, cases in which CSCI therapy was started at our hospital were investigated. Background: Continuous subcutaneous infusion…Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial
Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…
- 1
- 2
- 3
- …
- 62
- Next Page »